BioArctic AB (OSTO:BIOA B)
kr 238.4 5 (2.14%) Market Cap: 21.06 Bil Enterprise Value: 20.57 Bil PE Ratio: 0 PB Ratio: 21.21 GF Score: 55/100

Q1 2021 BioArctic AB Earnings Call Transcript

Apr 21, 2021 / 07:30AM GMT
Release Date Price: kr92.6 (+2.66%)
Operator

Welcome to the BioArctic Q1 Report 2021. Today, I am pleased to present CEO, Gunilla Osswald and CFO, Jan Mattsson. (Operator Instructions) Speakers, please begin.

Gunilla Osswald;publ;CEO
BioArctic AB

()-

So welcome to BioArctic's First Quarter Report 2021. I'm Gunilla Osswald, and I'm the CEO of BioArctic. I will share the presentation here today with our CFO, Jan Mattsson.

This year has started really well for BioArctic. Our most advanced program, lecanemab, BAN2401, in Alzheimer's disease, has further been strengthened by new data and other data in the Alzheimer's field. Our partner, Eisai, has completed enrollment of patients into the pivotal Clarity AD study. And our Phase IIb results have been published.

Our project portfolio has progressed well and expanded during the first quarter of this year, and I will describe more about this in the presentation here today.

Next slide, please. BioArctic is listed on Nasdaq Stockholm Mid-Cap, and this is our disclaimer.

Next slide, please.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot